Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 14/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 14/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 14/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 13/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25974996 | 0.78 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL1106491 | 0.76 | KDM4E (0.44) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL27446368 | 0.74 | PTGS2 (0.40) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL10119732 | 0.74 | PTGS2 (0.47) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL20048155 | 0.74 | ADORA2A (0.44) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL506044 | 0.74 | ADORA2A (0.38) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL1106469 | 0.74 | PTGDR2 (0.42) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL14757564 | 0.74 | ADORA2A (0.38) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL1106476 | 0.74 | ADORA2A (0.51) | ADORA2AADORA1PTGS2BMPR1AACVRL1 | |
| SCHEMBL31313750 | 0.71 | TYR (0.42) | ADORA2AADORA1PTGS2BMPR1AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2760854-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| CN-102459225-A | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | disclosed |
| EP-2419417-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | ADORA2A 244/4885ADORA1 163/4885PTGS2 341/4885 |
| US-20130085164-A1 | Imidazole Derivatives | CYP17A1, CYP2A7, CYP11B1 | ADORA2A 4382/4885ADORA1 4067/4885PTGS2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.